FIELD: pharmaceutics.
SUBSTANCE: invention relates to a condensed heterocyclic compound of the general formula (I) or its enantiomer, diastereomer, racemate and mixture thereof, where R1 and R2 are each independently selected from a group consisting of hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C6-C10 aryl; and R1 and R2 are not both hydrogen or R1 and R2 and neighboring -(CH2)n-O and bound carbon atoms together form unsubstituted 5-element heterocyclic ring, wherein the specified heterocyclic ring is thiophene; each R3, R4 is independently selected from a group consisting of hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-element heterocyclic ring, which is selected from thiophene, furan and pyrrole, unsubstituted benzyl, -SO2R9; R5 is selected from a group consisting of hydrogen or halogen; R6 and R7 are each independently selected from a group consisting of hydrogen, unsubstituted C1-C2 alkyl, unsubstituted C1-C2 alkoxy, -OSO2R9; R8 is hydrogen; R9 and R10 are independently hydrogen, unsubstituted C1-C6 alkyl or unsubstituted C6 cycloalkyl, C6-C10 aryl unsubstituted or substituted with 1 halogen, benzyl; wherein, if both of R3 and R4 are hydrogen, then at least one of R1, R2, R6, R7 is a group selected from a group consisting of substituted C6-C10 aryl; where “substituted” means that one, two or three hydrogen atoms in the group are substituted by a substituent selected from a group consisting of halogen, C1-C2 alkyl unsubstituted or substituted with three halogens, C1 alkoxy, hydroxy, cyano, unsubstituted 5-element heterocyclic ring selected from pyrazole, -NR9R10, -SO2R9, -OSO2R9, -COOR9 and -OCOR9; n is 1. The invention also relates to specific condensed heterocyclic compounds, a method for obtaining a compound of the formula (I) and a pharmaceutical composition based on a compound of the formula (I).
EFFECT: obtaining of a new condensed heterocyclic compounds useful for the treatment of metabolic diseases.
13 cl, 6 tbl, 414 ex
Title | Year | Author | Number |
---|---|---|---|
PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | 2017 |
|
RU2711991C1 |
COMPOUNDS OF C, O-SPIRO-ARYLGLYCOSIDES, THEIR PREPARATION AND USE | 2016 |
|
RU2746858C2 |
INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | 2015 |
|
RU2719428C2 |
FLUORINATED COMPOUND OF CYCLOPROPYLAMINE, THE METHOD OF PREPARATION, THE PHARMACEUTICAL COMPOSITION AND ITS USE | 2017 |
|
RU2746323C2 |
ISOINDOLINE COMPOUND, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND THEIR USE | 2019 |
|
RU2813232C2 |
DERIVATIVES OF PYRIDINE AND APPLICATION THEREOF AGAINST MICROBACTERIA | 2015 |
|
RU2664587C1 |
SERIN / TREONIN KINASE INHIBITORS FOR TREATING OF HYPEROPLIFERATIVE DISEASES | 2013 |
|
RU2644947C2 |
COMPOUNDS OF THIENYL[3, 2-d]PYRIMIDINE-4-ON, METHOD FOR PRODUCTION, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2012 |
|
RU2624021C2 |
O-AMINOHETEROARYLALKYNYL CONTAINING COMPOUND, METHOD FOR ITS PRODUCTION AND ITS USE | 2018 |
|
RU2797694C2 |
PYRROLO[2,1-f][1,2,4]TRIAZINE COMPOUND, METHOD FOR PRODUCTION AND USE THEREOF | 2013 |
|
RU2589053C1 |
Authors
Dates
2021-09-28—Published
2017-03-29—Filed